Valsartan is used clinical for receptor antagonist of angiotensin AT1, has good effect to the different degree of hypertension patients who used other antihypertensive without efficacy , is a new generation of highly efficient antihypertensive .
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, valsartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium.
Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.
Valsartan is an angiotensin II receptor antagonistwith particularly high affinity for the type I (AT1) angiotensin receptor. By blocking the action of angiotensin, valsartan dilates blood vessels and reduces blood pressure. In the U.S., valsartan is indicated for treatment of high blood pressure, congestive heart failure (CHF), or post-myocardial infarction (MI) .
Me gelek kargehên kalîteya bilind bi hevkariyek kûr heye, ku dikarin ji we re hilberên kalîteya bilind û bihayên reqabetê peyda bikin. Û em dikarin ji bo kirînên mezin erzanan jî bidin. Û em bi gelek pargîdaniyên barkêş ên profesyonel re hevkariyê dikin, dikarin hilberan bi ewlehî û bi aramî radestî destên we bikin. Dema radestkirinê piştî pejirandina dravdanê 3-20 rojan e.
Şanî | Test Standard | Testing Result | |
Xuyabûnî | Powder | Lihev dike | |
Color | Toza spî | Lihev dike | |
Particle Size | 100% pass 80 mesh | Lihev dike | |
Oder | Characteristic | Lihev dike | |
Taste | Characteristic | Lihev dike | |
Windakirina li ser Drying | ≤5.0% | 2.20% | |
Residue on Ignition | ≤0.1% | 0.05% | |
Residual acetone | ≤0.1% | Lihev dike | |
Residual Ethanol | ≤0.5% | Lihev dike | |
Heave Mentals | ≤10ppm | Lihev dike | |
Na | ≤0.1% | <0.1% | |
Pb | ≤3 ppm | Lihev dike | |
Total Plate | <1000CFU/g | Lihev dike | |
Yeast & Mold | <100 CFU /g | Lihev dike | |
E. Coli | Nebaş | Lihev dike | |
Salmonella | Nebaş | Lihev dike | |
Conclusion: Conform with USP Standard |
1. Ma hûn kargehek an pargîdaniyek bazirganî ne?
Em pargîdaniyek in ku pîşesazî û bazirganiyê entegre dike, karûbarê yek-stop peyda dike. OEM dikare were pejirandin.
2. Ma hûn nimûne pêşkêş dikin? Ew belaş an zêde ye?
Nimûneyên belaş. Pêdivî ye ku heqê barkirina nimûneyê ji hêla we ve were dayîn.
3. Hûn belgeyên ku bi kontrola kalîteyê ve girêdayî ne?
Sertîfîkaya ISO 9001: 2008 ji bo misogerkirina kalîteyê.
4. Divê ez çi peyda bikim da ku jêderkek bistînim?
Ji kerema xwe celebê hilberê ku hûn hewce ne, hêjmara fermanê, navnîşan û hewcedariyên taybetî me agahdar bikin. Dê di wextê de ji bo referansa we veqetandin were çêkirin.
5. Hûn rêbazek dravdanê çawa tercîh dikin? Mercên çawa têne qebûl kirin?
Mercên Radestkirina Pejirandî: FOB, CFR, CIF, EXW;
Pereyê Tezmînata Qebûlkirî:USD;
Accepted Payment Type: T/T,Western Union; Paypal,BTC
Zimanê axaftinê: Îngilîzî.
Kategoriyên hilberan